316 related articles for article (PubMed ID: 24599273)
1. High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic control.
Neumann T; Lodes S; Kästner B; Franke S; Kiehntopf M; Lehmann T; Müller UA; Wolf G; Sämann A
Osteoporos Int; 2014 May; 25(5):1527-33. PubMed ID: 24599273
[TBL] [Abstract][Full Text] [Related]
2. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes.
Yamamoto M; Yamaguchi T; Yamauchi M; Sugimoto T
Diabetes Care; 2009 Dec; 32(12):2263-8. PubMed ID: 19752174
[TBL] [Abstract][Full Text] [Related]
3. Ratio of Endogenous Secretory Receptor for Advanced Glycation End Products to Pentosidine Predicts Fractures in Men.
Tamaki J; Kouda K; Fujita Y; Iki M; Yura A; Miura M; Sato Y; Okamoto N; Kurumatani N
J Clin Endocrinol Metab; 2018 Jan; 103(1):85-94. PubMed ID: 29040721
[TBL] [Abstract][Full Text] [Related]
4. Trabecular bone score in type 1 diabetes--a cross-sectional study.
Neumann T; Lodes S; Kästner B; Lehmann T; Hans D; Lamy O; Müller UA; Wolf G; Sämann A
Osteoporos Int; 2016 Jan; 27(1):127-33. PubMed ID: 26187124
[TBL] [Abstract][Full Text] [Related]
5. Pentosidine and carboxymethyl-lysine associate differently with prevalent osteoporotic vertebral fracture and various bone markers.
Nakano M; Nakamura Y; Suzuki T; Miyazaki A; Takahashi J; Saito M; Shiraki M
Sci Rep; 2020 Dec; 10(1):22090. PubMed ID: 33328494
[TBL] [Abstract][Full Text] [Related]
6. Urinary Pentosidine levels negatively associates with trabecular bone scores in patients with type 2 diabetes mellitus.
Choi YJ; Ock SY; Jin Y; Lee JS; Kim SH; Chung Y-
Osteoporos Int; 2018 Apr; 29(4):907-915. PubMed ID: 29322222
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density at femoral neck and lumbar spine in adults with type 1 diabetes: a meta-analysis and review of the literature.
Shah VN; Harrall KK; Shah CS; Gallo TL; Joshee P; Snell-Bergeon JK; Kohrt WM
Osteoporos Int; 2017 Sep; 28(9):2601-2610. PubMed ID: 28580510
[TBL] [Abstract][Full Text] [Related]
8. Bone Mineral Density across the Lifespan in Patients with Type 1 Diabetes.
Halper-Stromberg E; Gallo T; Champakanath A; Taki I; Rewers M; Snell-Bergeon J; Frohnert BI; Shah VN
J Clin Endocrinol Metab; 2020 Mar; 105(3):746-53. PubMed ID: 31676897
[TBL] [Abstract][Full Text] [Related]
9. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
[TBL] [Abstract][Full Text] [Related]
10. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
Ghanem AA; Elewa A; Arafa LF
Eur J Ophthalmol; 2011; 21(1):48-54. PubMed ID: 20544678
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density predictors in long-standing type 1 and type 2 diabetes mellitus.
Bilha SC; Leustean L; Preda C; Branisteanu DD; Mihalache L; Ungureanu MC
BMC Endocr Disord; 2021 Aug; 21(1):156. PubMed ID: 34362364
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive skin autofluorescence, blood and urine assays of the advanced glycation end product (AGE) pentosidine as an indirect indicator of AGE content in human bone.
Kida Y; Saito M; Shinohara A; Soshi S; Marumo K
BMC Musculoskelet Disord; 2019 Dec; 20(1):627. PubMed ID: 31881872
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products are not associated with bone mineral density, trabecular bone score, and bone turnover markers in adults with and without type 1 diabetes: a cross-sectional study.
Coll JC; Turcotte AF; Leslie WD; Michou L; Weisnagel SJ; Mac-Way F; Albert C; Berger C; Morin SN; Rabasa-Lhoret R; Gagnon C
JBMR Plus; 2024 Feb; 8(3):ziad018. PubMed ID: 38505219
[TBL] [Abstract][Full Text] [Related]
14. Plasma pentosidine levels are associated with prevalent fractures in patients with chronic liver disease.
Saeki C; Saito M; Kanai T; Nakano M; Oikawa T; Torisu Y; Saruta M; Tsubota A
PLoS One; 2021; 16(4):e0249728. PubMed ID: 33798236
[TBL] [Abstract][Full Text] [Related]
15. Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with Type 1 diabetes.
Neumann T; Sämann A; Lodes S; Kästner B; Franke S; Kiehntopf M; Hemmelmann C; Lehmann T; Müller UA; Hein G; Wolf G
Diabet Med; 2011 Jul; 28(7):872-5. PubMed ID: 21395677
[TBL] [Abstract][Full Text] [Related]
16. Changes in the albumin glycation site, plasma pentosidine and esRAGE concentrations before and after intensive diabetic treatment in patients with abnormally high glycated albumin levels.
Miyamoto H; Kohzuma T; Ohnishi A
Ann Clin Biochem; 2018 Jan; 55(1):84-91. PubMed ID: 28504612
[TBL] [Abstract][Full Text] [Related]
17. Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men.
Lamb LS; Alfonso H; Norman PE; Davis TME; Forbes J; Müench G; Irrgang F; Almeida OP; Golledge J; Hankey GJ; Flicker L; Yeap BB
J Clin Endocrinol Metab; 2018 Nov; 103(11):4224-4231. PubMed ID: 30137355
[TBL] [Abstract][Full Text] [Related]
18. Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study.
Gineyts E; Munoz F; Bertholon C; Sornay-Rendu E; Chapurlat R
Osteoporos Int; 2010 Feb; 21(2):243-50. PubMed ID: 19421701
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study.
Schwartz AV; Backlund JC; de Boer IH; Rubin MR; Barnie A; Farrell K; Trapani VR; Gregory NS; Wallia A; Bebu I; Lachin JM; Braffett BH; Gubitosi-Klug R;
Lancet Diabetes Endocrinol; 2022 Jul; 10(7):509-518. PubMed ID: 35576955
[TBL] [Abstract][Full Text] [Related]
20. The association of urinary pentosidine levels with the prevalence of osteoporotic fractures in postmenopausal women.
Shiraki M; Kashiwabara S; Imai T; Tanaka S; Saito M
J Bone Miner Metab; 2019 Nov; 37(6):1067-1074. PubMed ID: 31214839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
